批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2006/04/13 |
ORIG-1(原始申请) |
Approval |
Type 2 - New Active Ingredient |
PRIORITY
;Orphan
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2023/10/25 |
SUPPL-14(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2021/03/26 |
SUPPL-12(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2019/08/14 |
SUPPL-11(补充) |
Approval |
Labeling-Container/Carton Labels |
STANDARD
;Orphan
|
|
|
| 2017/10/16 |
SUPPL-10(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2016/01/13 |
SUPPL-9(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2013/12/03 |
SUPPL-8(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2013/02/28 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
| 2009/12/22 |
SUPPL-4(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2008/09/12 |
SUPPL-3(补充) |
Approval |
Labeling |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:IBUPROFEN LYSINE; 剂型/给药途径:INJECTABLE;INTRAVENOUS; 规格:EQ 20MG BASE/2ML (EQ 10MG BASE/ML); 治疗等效代码:AP<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 021903 |
001 |
NDA |
NEOPROFEN |
IBUPROFEN LYSINE |
INJECTABLE;INTRAVENOUS |
EQ 20MG BASE/2ML (EQ 10MG BASE/ML) |
Prescription |
Yes |
Yes |
AP |
2006/04/13
|
RECORDATI RARE |
| 202402 |
001 |
ANDA |
IBUPROFEN LYSINE |
IBUPROFEN LYSINE |
INJECTABLE;INTRAVENOUS |
EQ 20MG BASE/2ML (EQ 10MG BASE/ML) |
Prescription |
No |
No |
AP |
2016/03/30
|
XGEN PHARMS |